anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
BioAtla · pitchdeck

BioAtla | Investor Presentation Deck | 55 slides

55 pages · 5 arc beats · 3 loops

Pitchdeck Download JSON
Unlock

BioAtla | Investor Presentation Deck | 55 slides

BioAtla · 2024-01
arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON
Narrative range 21 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 7 hits
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides
— 0/1 slides
Traction 11 slides 100% 11/11 slides 100% 11/11 slides · 49 hits
— 0/11 slides
45.5% 5/11 slides 36.4% 4/11 slides 100% 11/11 slides 100% 11/11 slides · 22 hits Market Sizing 6 slides 100% 6/6 slides 100% 6/6 slides · 42 hits
— 0/6 slides
83.3% 5/6 slides · 6 hits 16.7% 1/6 slides 100% 6/6 slides
— 0/6 slides
Why Now 2 slides 100% 2/2 slides 100% 2/2 slides · 6 hits
— 0/2 slides
50% 1/2 slides · 2 hits 50% 1/2 slides 100% 2/2 slides
— 0/2 slides

Slide inventory

55
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detail
02
other
Open slide detail
03
The slide uses a linked-circle diagram to represent the company's core pillars.summarize
Open slide detail
04
other
Open slide detail
05
other
Open slide detail
06
The slide uses a visual comparison between healthy cells (alkaline) and cancer cells (acidic) to illustrate the binding mechanism.present_solution
Open slide detailBeat · Solution
07
The slide uses a three-column layout to compare different therapeutic modalities enabled by the same platform technology.present_solution
Open slide detail
08
The chart uses a Gantt-style visualization to show the progress of drug candidates through clinical phases.plan_implementation
Open slide detailLoop · Quick Win Big Bet
09
transition
Open slide detailLoop · Quick Win Big Bet
10
The slide uses a visual comparison framework to illustrate the mechanism of action (MOA) of the drug candidate.present_solution
Open slide detailLoop · Quick Win Big Bet
11
The chart uses a dot plot format to show the occurrence of specific GI symptoms over a 29-day study period across different subjects.show_traction
Open slide detailBeat · TractionLoop · Quick Win Big Bet
12
The diagram illustrates a dose escalation study design with combination therapy.plan_implementation
Open slide detailBeat · TractionLoop · Quick Win Big Bet
13
Data cut date: 15Nov23analyze_data
Open slide detailBeat · TractionLoop · Quick Win Big Bet
14
Data cut date: 15Nov23. Pt = Platinum.analyze_data
Open slide detailBeat · TractionLoop · Quick Win Big Bet
15
Data table showing safety profile by dose cohort.analyze_data
Open slide detailBeat · TractionLoop · Quick Win Big Bet
16
The slide highlights a low incidence of immune-related adverse events (2 out of 18 patients).analyze_data
Open slide detailBeat · TractionLoop · Quick Win Big Bet
17
This is a classic 'spider plot' or 'swimmer plot' variant used in oncology clinical trials to visualize individual patient tumor burden changes over time.show_traction
Open slide detailBeat · TractionLoop · Quick Win Big Bet
18
The chart is a spider plot (or swimmer plot variant) showing change in target lesion size over time for individual patients.show_traction
Open slide detailBeat · TractionLoop · Quick Win Big Bet
19
Before-after medical imaging comparison.show_traction
Open slide detailBeat · TractionLoop · Quick Win Big Bet
20
The slide uses a before-and-after medical imaging comparison to demonstrate drug efficacy.illustrate_case
Open slide detailBeat · TractionLoop · Quick Win Big Bet
21
The table tracks 3 patients across different cancer types, detailing their age, prior treatments, adverse events, dose-limiting toxicities (DLT), cycles completshow_traction
Open slide detailBeat · TractionLoop · Quick Win Big Bet
22
The slide uses a process flow diagram to map patient segments to specific dosing regimens and clinical goals.plan_implementation
Open slide detail
23
transition
Open slide detail
24
The slide uses a 2x2 grid of metrics to frame the problem/opportunity.size_opportunity
Open slide detailBeat · Market Sizing
25
Includes comparative context to historical studies (pazopanib, pembrolizumab).show_traction
Open slide detailBeat · Market Sizing
26
Includes decision criteria for 'Go'/'No Go' based on clinical response and PFS rates.analyze_data
Open slide detailBeat · Market Sizing
27
Includes specific adverse event data and clinical observations.show_traction
Open slide detailBeat · Market Sizing
28
Details specific patient enrollment numbers (~80 total, ~60 for primary analysis) and dosing randomization criteria.plan_implementation
Open slide detailBeat · Market Sizing
29
The slide uses a grid of metrics to define the addressable market and the clinical problem (progression after 1L).size_opportunity
Open slide detailBeat · Market Sizing
30
The slide presents clinical evidence linking AXL expression to poor patient outcomes in two different cohorts.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
31
The slide outlines a clinical trial protocol including patient disposition criteria and study endpoints.present_framework
Open slide detail
32
The table highlights the heavy pretreatment status of the patient population, specifically noting that a significant portion received 3 or more prior systemic tanalyze_data
Open slide detail
33
Includes specific response rates, disease control rates, and confidence intervals for two patient cohorts.show_traction
Open slide detail
34
Waterfall plot shows best percentage change from baseline; spider plot shows change over time in weeks.show_traction
Open slide detail
35
This is a classic swimmer plot used in oncology clinical trials to visualize time-on-treatment and response status.show_traction
Open slide detail
36
Includes PET scan imagery comparing baseline to post-treatment status.show_traction
Open slide detail
37
Data presented at IASLC 2023 North America Conference on Lung Cancer.analyze_data
Open slide detail
38
Data cut date: 30Jun23. Includes events occurring in >=15% of patients or grade >=3 in >=3% of patients.analyze_data
Open slide detail
39
Mentions FDA Project Optimus, which is a regulatory initiative for dose optimization in oncology trials.show_traction
Open slide detail
40
The dashed box highlights the 'AXL low' expression group, showing significant anti-tumor activity.show_traction
Open slide detail
41
plan_implementation
Open slide detail
42
transition
Open slide detail
43
Includes footnotes for data sources and a glossary of terms.size_opportunity
Open slide detail
44
The chart is a waterfall plot showing percentage change in tumor size. Red bars indicate partial response (PR).show_traction
Open slide detail
45
Uses a 2x2 grid layout to present key market metrics alongside current treatment efficacy benchmarks.size_opportunity
Open slide detail
46
Includes specific patient counts and clinical outcomes (responses, stable disease, progressive disease).show_traction
Open slide detail
47
The slide uses a funnel-like logic to narrow down the addressable market from total prevalence to the 2L+ refractory segment.size_opportunity
Open slide detail
48
The slide uses a table to present clinical outcomes for specific cancer types, followed by a summary statement on the first-in-class status.show_traction
Open slide detail
49
The table displays specific drug administration schedules for clinical evaluation.analyze_data
Open slide detail
50
The table tracks specific dosing schedules (Q2W, 3Q4W, 2Q3W) and their progression status.analyze_data
Open slide detail
51
transition
Open slide detail
52
The slide uses a before-after-bridge style framing to contrast the problem (toxicity in standard bispecifics) with the solution (BA3182).present_solution
Open slide detail
53
The slide details the dose escalation strategy using accelerated, standard, and priming titration cohorts.plan_implementation
Open slide detail
54
The slide uses a simple 2-column table structure to represent a timeline.plan_implementation
Open slide detailBeat · Why Now
55
Uses a Venn-like diagram to connect technology, pipeline, and financial status.summarize
Open slide detailBeat · Why Now